Show simple item record

AuthorChemaitelly, Hiam
AuthorTang, Patrick
AuthorHasan, Mohammad R
AuthorAlMukdad, Sawsan
AuthorYassine, Hadi M
AuthorBenslimane, Fatiha M
AuthorAl Khatib, Hebah A
AuthorCoyle, Peter
AuthorAyoub, Houssein H
AuthorAl Kanaani, Zaina
AuthorAl Kuwari, Einas
AuthorJeremijenko, Andrew
AuthorKaleeckal, Anvar H
AuthorLatif, Ali N
AuthorShaik, Riyazuddin M
AuthorAbdul Rahim, Hanan F
AuthorNasrallah, Gheyath K
AuthorAl Kuwari, Mohamed G
AuthorAl Romaihi, Hamad E
AuthorButt, Adeel A
AuthorAl-Thani, Mohamed H
AuthorAl Khal, Abdullatif
AuthorBertollini, Roberto
AuthorAbu-Raddad, Laith J
Available date2021-10-21T05:10:45Z
Publication Date2021-10-06
Publication NameNew England Journal of Medicine
Identifierhttp://dx.doi.org/10.1056/NEJMoa2114114
CitationChemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., ... & Abu-Raddad, L. J. (2021). Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. New England Journal of Medicine.
ISSN0028-4793
URIhttp://hdl.handle.net/10576/24611
AbstractWaning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear. We used a matched test-negative, case-control study design to estimate vaccine effectiveness against any SARS-CoV-2 infection and against any severe, critical, or fatal case of Covid-19, from January 1 to September 5, 2021. Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months. BNT162b2-induced protection against SARS-COV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose. (Funded by Weill Cornell Medicine-Qatar and others.).
Languageen
PublisherMassachusetts Medical Society
SubjectBNT162b2
SARS-CoV-2
vaccine
TitleWaning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar.
TypeArticle
ESSN1533-4406
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record